Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 6/20 | 0.46 |
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16626925 | 0.93 | CYP1A2 (0.64) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL13138386 | 0.90 | CYP1A2 (0.72) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL15608320 | 0.88 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL18167329 | 0.88 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL28777391 | 0.88 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL12934327 | 0.88 | CYP1A2 (0.77) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL29739948 | 0.87 | SMN1; SMN2 (0.65) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL28943389 | 0.87 | SMN1; SMN2 (0.65) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL25003377 | 0.87 | CYP1A2 (0.55) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL9679571 | 0.87 | CYP1A2 (0.55) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040261-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150099806-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY | 2015-04-09 | — | — | US | disclosed |
| US-8916609-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916609-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2014-12-23 | — | — | US | disclosed |
| US-8450089-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450089-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120316236-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY | 2012-12-13 | — | — | US | disclosed |
| US-20120316236-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY | 2012-12-13 | — | — | US | disclosed |
| US-20110177173-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-21 | — | — | US | disclosed |
| US-20110177173-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-21 | — | — | US | disclosed |
| WO-2011062640-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099806-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | ATP6V1B1, GLS, REN | CYP1A2 2776/4885CYP2C9 1461/4885CYP2C19 2452/4885 |
| US-20110177173-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | GLS, PKD1, CLIC1 | CYP1A2 2598/4885CYP2C9 1819/4885CYP2C19 2603/4885 |
| US-20120316236-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | ATP6V1B1, GLS, REN | CYP1A2 2776/4885CYP2C9 1461/4885CYP2C19 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.